Men's Health News

RSS

Low testosterone levels to blame for low libido, fatigue and weight gain

While most frequently associated with women's health, age-related hormone changes, often dubbed menopause, can occur in men as well, causing symptoms of fatigue, mood swings, decreased desire for sex, hair loss, lack of concentration and weight gain. Experts estimate that more than 5 million men are affected, yet worry the number may be considerably higher since symptoms are frequently ignored.

21 Aug 2010

Us TOO International Prostate Cancer Education & Support Network recognized for 20 years of service

The prostate cancer community joins together in congratulating Us TOO International Prostate Cancer Education & Support Network in their 20th anniversary of continued prostate cancer support, education and advocacy.

19 Aug 2010

Scientists study yeast to understand human pathologies affecting male fertility

Men and yeast have something in common: they use the same molecular process to ensure the integrity of their gene pool during reproduction. This is a recent finding by researchers from CNRS, Inserm and the Université Joseph Fourier in Grenoble. The scientists are therefore set on studying yeast in order to shed light on the numerous cases of male infertility related to the malfunction of this process during spermatogenesis.

19 Aug 2010

Aggressive children more inclined to misuse drugs

Aggressive and hyperactive boys with low parental monitoring are more likely to befriend deviant peers and become heavy drug users as teens, according to a new study published in the journal Addictive Behaviors. Yet the investigation by scientists from the Universit- de Montr-al and Sainte-Justine University Hospital Research Center found that bad boys can be protected from heavy substance use as teenagers if they are highly monitored and befriend good boys as children.

18 Aug 2010

Loyola University Medical Center to offer free prostate cancer screenings

More than 55 million American men are at risk for developing prostate cancer, according to the American Cancer Society. This year more than 27,000 men are expected to die of the disease, which is the second-leading cause of cancer death in men.

18 Aug 2010

Palatin reports positive results from bremelanotide Phase 1 trial for sexual dysfunction

Palatin Technologies, Inc. today announced positive results of a Phase 1 clinical trial of subcutaneously administered bremelanotide, its melanocortin agonist drug candidate for treatment of male erectile dysfunction (ED) and female sexual dysfunction (FSD). The results demonstrate that with subcutaneous administration consistent therapeutic blood plasma levels can be obtained without sustained clinically significant blood pressure effects and support the continued development of bremelanotide.

17 Aug 2010

Involuntary childlessness affects couples more negatively than previously reported

Test-tube fertilisation is the reason why more couples than previously now have the chance to become biological parents. However, the path to achieving this can be laborious and, for some, the treatment is unsuccessful. A thesis from the University of Gothenburg, Sweden, indicates that people are more negatively affected than previously reported in studies of involuntary childlessness.

16 Aug 2010

Cancer Research Technology grants Valirx global rights to develop VAL 201 for cancer treatment

Cancer Research Technology has signed a deal to provide biotech company ValiRx plc with the global rights to develop a promising compound to treat hormone-resistant prostate cancer.The compound, now called VAL 201, has been shown in pre-clinical tests in mice to stop growth of tumours which have been unresponsive to hormone treatments. VAL 201 blocks genes which can cause prostate cancer to develop. The compound has been shown to be effective in treating mice with breast and prostate cancer and is now rapidly progressing towards the first clinical trials in patients.

13 Aug 2010

Repros receives US patent for Androxal

Repros Therapeutics Inc. today announced the US Patent and Trademark office has issued U.S. Patent No. 7,759,360 for Androxal, the Company's lead program for the treatment of low testosterone in men. This patent specifically claims methods and materials for the treatment of testosterone deficiency in men with secondary hypogonadism. Repros has over 35 issued or pending US and European patents involving Androxal.

11 Aug 2010

Magnetic resonance image analysis helps assessment of prostate cancer severity

Rutgers researchers are developing methods that can accurately assess the severity of prostate cancer by analyzing magnetic resonance images and spectra of a patient's prostate gland. This may help physicians decide more confidently which patients need aggressive treatment and which are better served by "watchful waiting," and could even postpone or eliminate invasive biopsies in patients with low-grade tumors.

11 Aug 2010

Study shows physicians reluctant to use finasteride for prostate cancer

Despite the dramatic results of the Prostate Cancer Prevention Trial (PCPT), which showed a significant reduction in prostate cancer among those taking finasteride, physicians have not increased its use, according to a study published in the September issue of Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

11 Aug 2010

AMS AdVance XP sling for male stress urinary incontinence receives CE Mark

American Medical Systems, a leading provider of world-class devices and therapies for both male and female pelvic health, announced today the company received CE Mark for AdVance XP. The device is the latest generation of AMS' AdVance sling, a minimally invasive implant for the treatment of male stress urinary incontinence (SUI).

9 Aug 2010

Aragon initiates dosing in ARN-509 Phase 1/2 clinical trial for castration-resistant prostate cancer

Aragon Pharmaceuticals today announced the dosing of the first patient in a Phase 1/2 clinical trial of the company's lead compound, ARN-509, in patients with castration-resistant prostate cancer (CRPC).

9 Aug 2010

Surgery offers high survival rate for prostate cancer patients: Study

Surgery for localized prostate cancer offers a significantly higher survival rate than either external-beam radiation or hormonal therapies, according to a new study led by researchers at UCSF.The differences among therapies were more prominent at higher levels of cancer risk, and suggest, the researchers say, that in many cases surgery should play a greater role in treatment strategies for patients with prostate cancer that is likely to recur or spread.

7 Aug 2010

New laser technology for robotic prostate cancer surgery

One of the challenges of prostate cancer surgery is removing the cancer-affected gland without side effects. The procedure is estimated to cause long-term sexual dysfunction in half of men.Now, new published research by urologic surgeons at NewYork-Presbyterian Hospital/Columbia University Medical Center presents evidence that a new laser technology used with robotic prostate cancer surgery may reduce the risk of damaging the crucial nerves necessary for erections and urinary continence.

6 Aug 2010

$Aeterna Zentaris announces $1.5M NIH award for AEZS-108 Phase 1/2 study in refractory prostate cancer$

Aeterna Zentaris announces $1.5M NIH award for AEZS-108 Phase 1/2 study in refractory prostate cancer

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that the National Institutes of Health ("NIH") has awarded Dr. Jacek Pinski, Associate Professor of Medicine at the Norris Comprehensive Cancer Center of the University of Southern California, a grant of about US$1.5 million over three years to conduct a Phase 1/2 study in refractory prostate cancer with the Company's doxorubicin LHRH receptor targeted conjugate compound, AEZS-108.

5 Aug 2010

Study to understand processes that lead to onset of testicular germ cell cancer

Scientists have developed a model that will enable them to investigate, for the first time, how human testes develop in baby boys while they are in the womb. Until now it has been impossible to study testicular development during pregnancy in humans and this discovery will enable researchers to understand the processes that can lead to the onset of testicular germ cell cancer (TGCC) in young adult life, and how factors, such as common environmental chemicals, might play a role.

4 Aug 2010

Bisphenol A may decrease sperm quality, concentration: Research

In one of the first human studies of its kind, researchers have found that urinary concentrations of the controversial chemical Bisphenol A, or BPA, may be related to decreased sperm quality and sperm concentration.However, the researchers are quick to point out that these results are preliminary and more study is needed. Several studies have documented adverse effects of BPA on semen in rodents, but none are known to have reported similar relationships in humans.

4 Aug 2010

Effects of natural compound against prostate cancer published in Integrative Cancer Therapies

Researchers at Columbia University have published the dramatic effects of a natural 33-ingredient compound against prostate cancer cell lines. The impressive results are found in the most recent publication of Integrative Cancer Therapies.

3 Aug 2010

Study reveals potential marker for prostate cancer

Studies by a Purdue University-led team have revealed a potential marker for prostate cancer that could be the starting point for less invasive testing and improved diagnosis of the disease.

3 Aug 2010

Men's Health News

Low testosterone levels to blame for low libido, fatigue and weight gain

Us TOO International Prostate Cancer Education & Support Network recognized for 20 years of service

Scientists study yeast to understand human pathologies affecting male fertility

Aggressive children more inclined to misuse drugs

Loyola University Medical Center to offer free prostate cancer screenings

Palatin reports positive results from bremelanotide Phase 1 trial for sexual dysfunction

Involuntary childlessness affects couples more negatively than previously reported

Cancer Research Technology grants Valirx global rights to develop VAL 201 for cancer treatment

Repros receives US patent for Androxal

Magnetic resonance image analysis helps assessment of prostate cancer severity

Study shows physicians reluctant to use finasteride for prostate cancer

AMS AdVance XP sling for male stress urinary incontinence receives CE Mark

Aragon initiates dosing in ARN-509 Phase 1/2 clinical trial for castration-resistant prostate cancer

Surgery offers high survival rate for prostate cancer patients: Study

New laser technology for robotic prostate cancer surgery

Aeterna Zentaris announces $1.5M NIH award for AEZS-108 Phase 1/2 study in refractory prostate cancer

Study to understand processes that lead to onset of testicular germ cell cancer

Bisphenol A may decrease sperm quality, concentration: Research

Effects of natural compound against prostate cancer published in Integrative Cancer Therapies

Study reveals potential marker for prostate cancer

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Latest News